Metagenomi Therapeutics, Inc. (MGX)Healthcare | Biotechnology | EmeryVille, United States | NasdaqGS
1.19 USD
-0.02
(-1.653%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.20 +0.01 (0.840%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:31 a.m. EDT
The immediate outlook is severely clouded by deteriorating fundamentals and negative sentiment. The company recently reported a loss and missed revenue estimates, prompting analysts to cut their expectations and lower price targets. This negative catalyst is compounded by a significant multi-year price decline of nearly 37%, indicating that the market has already priced in substantial structural deterioration rather than viewing the current low valuation as a margin of safety. While the balance sheet currently shows a healthy current ratio and manageable debt relative to equity, the persistent negative free cash flow and negative returns on assets suggest the business model is struggling to generate value. With no dividend history to provide income, investors are left relying entirely on speculative capital gains in a sector where the stock has already fallen sharply from its highs. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.061084 |
| AutoETS | 0.074660 |
| AutoARIMA | 0.074661 |
| MSTL | 0.074790 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.925 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 33.509 |
| Revenue per Share | 0.361 |
| Market Cap | 44,954,756 |
| Forward P/E | -0.65 |
| Beta | 0.67 |
| Website | https://metagenomi.co |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.33516484 |
| Address1 | 5,959 Horton Street |
| Address2 | 7th Floor |
| All Time High | 12.74 |
| All Time Low | 1.13 |
| Ask | 1.54 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 139,590 |
| Average Daily Volume3 Month | 160,780 |
| Average Volume | 160,780 |
| Average Volume10Days | 139,590 |
| Beta | 0.672 |
| Bid | 0.864 |
| Bid Size | 2 |
| Book Value | 2.98 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.19 |
| Current Ratio | 4.504 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.24 |
| Day Low | 1.19 |
| Debt To Equity | 33.509 |
| Display Name | Metagenomi Therapeutics |
| Earnings Timestamp End | 1,755,115,200 |
| Earnings Timestamp Start | 1,755,115,200 |
| Ebitda | -95,402,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.398 |
| Enterprise To Revenue | -2.801 |
| Enterprise Value | -37,989,244 |
| Eps Current Year | -2.4175 |
| Eps Forward | -1.835 |
| Eps Trailing Twelve Months | -2.45 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2286 |
| Fifty Day Average Change | -0.038599968 |
| Fifty Day Average Change Percent | -0.031417847 |
| Fifty Two Week Change Percent | -33.516483 |
| Fifty Two Week High | 3.95 |
| Fifty Two Week High Change | -2.76 |
| Fifty Two Week High Change Percent | -0.69873416 |
| Fifty Two Week Low | 1.13 |
| Fifty Two Week Low Change | 0.060000062 |
| Fifty Two Week Low Change Percent | 0.0530974 |
| Fifty Two Week Range | 1.13 - 3.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 25,568,300 |
| Forward Eps | -1.835 |
| Forward P E | -0.6485014 |
| Free Cashflow | -50,950,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 113 |
| Fullday Change | -0.02 |
| Fullday Change Percent | -1.65289 |
| Fullday Price | 1.2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -75,035,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18899 |
| Held Percent Institutions | 0.18721001 |
| Implied Shares Outstanding | 37,777,105 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-02-09 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California. |
| Long Name | Metagenomi Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 44,954,756 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_633445224 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -93,462,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 45,710,297 |
| Number Of Analyst Opinions | 3 |
| Open | 1.2 |
| Operating Cashflow | -85,487,000 |
| Operating Margins | 111.9572 |
| Payout Ratio | 0.0 |
| Phone | 510 871 4880 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.8403353 |
| Post Market Price | 1.2 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 1.21 |
| Price Eps Current Year | -0.49224406 |
| Price Hint | 4 |
| Price To Book | 0.3993289 |
| Price To Sales Trailing12 Months | 3.315003 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.399 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -1.65289 |
| Regular Market Day High | 1.24 |
| Regular Market Day Low | 1.19 |
| Regular Market Day Range | 1.19 - 1.24 |
| Regular Market Open | 1.2 |
| Regular Market Previous Close | 1.21 |
| Regular Market Price | 1.19 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 78,034 |
| Return On Assets | -0.28186 |
| Return On Equity | -0.60611 |
| Revenue Per Share | 0.361 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 37,777,105 |
| Shares Percent Shares Out | 0.0385 |
| Shares Short | 1,453,190 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,543,288 |
| Short Name | Metagenomi Therapeutics, Inc. |
| Short Percent Of Float | 0.047399998 |
| Short Ratio | 10.03 |
| Source Interval | 15 |
| State | CA |
| Symbol | MGX |
| Target High Price | 9.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 120,664,000 |
| Total Cash Per Share | 3.194 |
| Total Debt | 37,720,000 |
| Total Revenue | 13,561,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.45045 |
| Two Hundred Day Average Change | -0.2604499 |
| Two Hundred Day Average Change Percent | -0.1795649 |
| Type Disp | Equity |
| Volume | 78,034 |
| Website | https://metagenomi.co |
| Zip | 94,608 |